Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ: SGMO )

2.560 -0.070 (-2.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
Soon After Novartis & Biogen Walked Away From Neurology Drug Partnerships, Sangamo Announces Major Restructuring
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced cutting 27% of its workforce, prioritizing its pipeline, and changing its corporate structure to save about $31 million to fund operations for at least... 
Via Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 479 stocks made new 52-week lows. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Sangamo Therapeutics
Via Benzinga
Earnings Preview For Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Boeing, Spirit AeroSystems And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 114 companies set new 52-week lows. 
Via Benzinga
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
UBS Group, Credit Suisse And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mostly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
10 Companies That Had Tons of Money in SVB When It Collapsed
Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB. 
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 135 companies reached new 52-week lows. 
Via Benzinga
Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
These cutting-edge biotech companies quickly fell out of favor with investors this week. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.